Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure

Angiotensin-converting enzyme inhibitors are effective vasodilators in the treatment of congestive heart failure. Enalapril, a new angiotensin-converting enzyme inhibitor, or placebo, in addition to digoxin and diuretic drugs, were given to 17 patients with chronic congestive heart failure who were followed up for 12 weeks. In random double-blind fashion, nine patients received enalapril and eight received placebo. Cardiac dimensions and function improved slightly but insignificantly in both groups. Treadmill exercise duration increased from a mean value (+/- standard deviation) of 9.1 +/- 3.2 to 12.0 +/- 3.5 minutes during enalapril administration (p less than 0.025) and was unchanged during placebo administration (10.1 +/- 3.7 versus 11.1 +/- 5.2 minutes). Maximal oxygen consumption also increased during enalapril therapy (15.8 +/- 3.4 to 18.4 +/- 4.4 ml/min per kg, p less than 0.05) and remained unchanged during placebo treatment (16.0 +/- 6.4 versus 17.0 +/- 4.6 ml/min per kg). Clinical functional class (Yale scale) improved 3.1 +/- 1.9 points (p less than 0.01) during enalapril treatment but not during placebo treatment (0.8 +/- 3.5 points, no significant difference). No significant side effects were observed. Thus, enalapril appears to be a clinically effective and useful new angiotensin-converting enzyme inhibitor for the management of chronic congestive heart failure.

This article has been cited by other articles:

				J. Abdulla, S. Z. Abildstrom, E. Christensen, L. Kober, and C. Torp-Pedersen A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction Eur J Heart Fail, December 1, 2004; 6(7): 927 - 935. [Abstract] [Full Text] [PDF]

				C. T. Pu, M. T. Johnson, D. E. Forman, J. M. Hausdorff, R. Roubenoff, M. Foldvari, R. A. Fielding, and M. A. F. Singh Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure J Appl Physiol, June 1, 2001; 90(6): 2341 - 2350. [Abstract] [Full Text] [PDF]

				W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]

				H. Kamishirado, T. Inoue, T. Fujito, M. Kase, M. Shimizu, Y. Sakai, K. Takayanagi, S. Morooka, S. Natsui, and H. Kamishirado Effect of Enalapril Maleate on Cerebral Blood Flow in Patients with Chronic Heart Failure Angiology, August 1, 1997; 48(8): 707 - 713. [Abstract] [PDF]

				The Large State Peer Review Organization Consortiu Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States Arch Intern Med, May 26, 1997; 157(10): 1103 - 1108. [Abstract] [PDF]

				R. Garg, S. Yusuf, the Collaborative Group on ACE Inhibitor Trials, W. D. Bussmann, P. Sleight, A. Uprichard, B. Massie, B. McGrath, B. Nilsson, B. Pitt, et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure JAMA, May 10, 1995; 273(18): 1450 - 1456. [Abstract] [PDF]

				D. W. Baker, M. A. Konstam, M. Bottorff, and B. Pitt Management of Heart Failure: I. Pharmacologic Treatment JAMA, November 2, 1994; 272(17): 1361 - 1366. [Abstract] [PDF]

				P. C. Deedwania Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Arch Intern Med, September 1, 1990; 150(9): 1798 - 1805. [Abstract] [PDF]

				R. Jaeschke and G. H. Guyatt Medical Therapy for Chronic Congestive Heart Failure Ann Intern Med, May 15, 1989; 110(10): 758 - 760. [Abstract] [PDF]

				W. N. Suki Renal Hemodynamic Consequences of Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure Arch Intern Med, March 1, 1989; 149(3): 669 - 673. [Abstract] [PDF]

				M. Packer Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results? Ann Intern Med, July 1, 1988; 109(1): 3 - 5. [Abstract] [PDF]

				P. R. Marantz, M. H. Alderman, and J. N. Tobin Diagnostic Heterogeneity in Clinical Trials for Congestive Heart Failure Ann Intern Med, July 1, 1988; 109(1): 55 - 61. [Abstract] [PDF]

				C. D. Mulrow, J. P. Mulrow, W. D. Linn, C. Aguilar, and G. Ramirez Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure: Implications of Randomized Trials JAMA, June 17, 1988; 259(23): 3422 - 3426. [Abstract] [PDF]

				M. PACKER, W. H. LEE, N. MEDINA, M. YUSHAK, and P. D. KESSLER Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure Ann Intern Med, March 1, 1987; 106(3): 346 - 354. [Abstract] [PDF]